Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.
Publication
, Journal Article
Spasojevic, I; da Costa, LRS; Horwitz, ME; Long, GD; Sullivan, KM; Chute, JP; Gasparetto, C; Morris, A; Chao, NJ; Rizzieri, DA
Published in: Cancer Invest
November 2012
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
November 2012
Volume
30
Issue
9
Start / End Page
679 / 682
Location
England
Related Subject Headings
- Transplantation Conditioning
- Therapeutic Equivalency
- Tandem Mass Spectrometry
- Oncology & Carcinogenesis
- Humans
- Hematopoietic Stem Cell Transplantation
- Chromatography, Liquid
- Busulfan
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Spasojevic, I., da Costa, L. R. S., Horwitz, M. E., Long, G. D., Sullivan, K. M., Chute, J. P., … Rizzieri, D. A. (2012). Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest, 30(9), 679–682. https://doi.org/10.3109/07357907.2012.726386
Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.” Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.
Spasojevic I, da Costa LRS, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012 Nov;30(9):679–82.
Spasojevic, Ivan, et al. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.” Cancer Invest, vol. 30, no. 9, Nov. 2012, pp. 679–82. Pubmed, doi:10.3109/07357907.2012.726386.
Spasojevic I, da Costa LRS, Horwitz ME, Long GD, Sullivan KM, Chute JP, Gasparetto C, Morris A, Chao NJ, Rizzieri DA. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012 Nov;30(9):679–682.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
November 2012
Volume
30
Issue
9
Start / End Page
679 / 682
Location
England
Related Subject Headings
- Transplantation Conditioning
- Therapeutic Equivalency
- Tandem Mass Spectrometry
- Oncology & Carcinogenesis
- Humans
- Hematopoietic Stem Cell Transplantation
- Chromatography, Liquid
- Busulfan
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis